Tazemetostat

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 274 publications

Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation.

Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation.

Journal: Science advances
Published: January 16, 2026

Update on pediatric soft tissue sarcomas.

Update on pediatric soft tissue sarcomas.

Journal: Current opinion in pediatrics
Published: December 26, 2025

Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Journal: Cancer investigation
Published: December 19, 2025

Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatform and Radionuclide Therapy.

Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatform and Radionuclide Therapy.

Journal: Molecular pharmaceutics
Published: November 22, 2025

Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives.

Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives.

Journal: RSC advances
Published: November 12, 2025

High-Grade Angiosarcoma Transformation in Schwannoma and SMARCB1 Mutation: A Case Report.

High-Grade Angiosarcoma Transformation in Schwannoma and SMARCB1 Mutation: A Case Report.

Journal: The American journal of case reports
Published: October 21, 2025

Opposing outcomes of short- and long-term epigenetic therapy in breast cancer: Implications for chemotherapy response.

Opposing outcomes of short- and long-term epigenetic therapy in breast cancer: Implications for chemotherapy response.

Journal: Biochemical pharmacology
Published: September 30, 2025

Deep learning and molecular dynamics reveal promising EZH2 inhibitors for epigenetic cancer targeting.

Deep learning and molecular dynamics reveal promising EZH2 inhibitors for epigenetic cancer targeting.

Journal: Computational biology and chemistry
Published: September 27, 2025

Design, synthesis and anti-tumor activities of pyridine-benzamide containing dithiocarbamate moiety as EZH2 inhibitors.

Design, synthesis and anti-tumor activities of pyridine-benzamide containing dithiocarbamate moiety as EZH2 inhibitors.

Journal: Bioorganic & medicinal chemistry
Published: September 26, 2025

Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer.

Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer.

Journal: FEBS letters
Published: September 19, 2025

EZH2 Inhibition in Mesothelioma Cells Increases the Release of Extracellular Vesicles That Skew Neutrophils Toward a Protumor Phenotype.

EZH2 Inhibition in Mesothelioma Cells Increases the Release of Extracellular Vesicles That Skew Neutrophils Toward a Protumor Phenotype.

Journal: International journal of molecular sciences
Published: September 04, 2025

EZH2-Mediated PTEN Silencing Promotes AKT-Dependent Afatinib Resistance in Radiation-Resistant Cervical Cancer Cells.

EZH2-Mediated PTEN Silencing Promotes AKT-Dependent Afatinib Resistance in Radiation-Resistant Cervical Cancer Cells.

Journal: Journal of clinical medicine
Published: August 27, 2025
Showing 1-12 of 274

Last Updated: 02/24/2026